FibroBiologics Seeks Reverse Split, Share Issuance Approvals

Ticker: FBLG · Form: DEF 14A · Filed: Dec 29, 2025 · CIK: 1958777

Sentiment: bearish

Topics: Reverse Stock Split, Share Dilution, Nasdaq Compliance, Special Meeting, Corporate Governance, Warrant Exercise, Biotechnology

Related Tickers: FBLG

TL;DR

**FBLG is pushing a reverse split and massive warrant exercises, signaling a desperate move to stay listed and a likely dilution hit for current shareholders.**

AI Summary

FibroBiologics, Inc. (FBLG) is calling a Special Meeting of Stockholders on February 20, 2026, to address critical corporate actions. The primary proposal is to approve a reverse stock split of its common and preferred stock at a ratio between 1-for-5 and 1-for-30, aimed at potentially boosting its stock price and maintaining Nasdaq listing compliance. Additionally, stockholders will vote on the issuance of up to 12,110,203 shares of common stock from a November 18, 2025 Securities Purchase Agreement, up to 4,477,614 shares from a November 24, 2025 SPA, and up to 313,433 shares related to an Engagement Letter for the November 24 SPA. Further, approval is sought for the issuance of up to 5,227,275 shares from a December 14, 2025 SPA and up to 365,909 shares from an Engagement Letter for the December SPA. These issuances, totaling 22,184,434 shares, are necessary to comply with Nasdaq Listing Rule 5635(d) following recent financing activities. CEO Pete O'Heeron, holding 2,500 Series C Preferred Stock shares with 13,000 votes each, effectively controls 32.8% of the total votes, with the Board committed to voting FOR all proposals.

Why It Matters

This DEF 14A filing is crucial for FBLG investors as it outlines proposals directly impacting share structure and potential dilution. The reverse stock split, if approved, could significantly alter the per-share price, potentially affecting investor sentiment and liquidity. The substantial issuance of 22,184,434 new shares, while necessary for recent financing, introduces significant dilution for existing shareholders. Competitively, maintaining Nasdaq listing through a reverse split is vital for FBLG's market visibility and access to capital, especially in the competitive biotech sector. Employees and customers are indirectly affected by the company's financial stability and ability to fund ongoing operations and research.

Risk Assessment

Risk Level: high — The risk level is high due to the proposed reverse stock split, which often precedes delisting or indicates underlying financial distress, and the significant potential for dilution from the issuance of up to 22,184,434 new shares. Furthermore, CEO Pete O'Heeron's control of 32.8% of total votes via 2,500 Series C Preferred Stock shares with 13,000 votes each, through an irrevocable proxy to the Board, concentrates voting power and limits minority shareholder influence.

Analyst Insight

Investors should carefully evaluate the potential for significant dilution from the 22,184,434 shares to be issued and the implications of a reverse stock split on FBLG's stock price and market perception. Consider reducing exposure if the dilution and reverse split do not align with your investment thesis, as these actions often signal underlying challenges.

Key Numbers

Key Players & Entities

FAQ

What is FibroBiologics, Inc. proposing at its Special Meeting of Stockholders?

FibroBiologics, Inc. is proposing an amendment to its Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-5 and 1-for-30. Additionally, it seeks approval for the issuance of up to 12,110,203 shares from a November 18, 2025 SPA, up to 4,477,614 shares from a November 24, 2025 SPA, up to 313,433 shares from an Engagement Letter, up to 5,227,275 shares from a December 14, 2025 SPA, and up to 365,909 shares from another Engagement Letter.

Why is FibroBiologics proposing a reverse stock split?

FibroBiologics is proposing a reverse stock split to potentially increase its per-share trading price, which is often a requirement to maintain compliance with Nasdaq's minimum bid price listing rules. The exact ratio, between 1-for-5 and 1-for-30, will be determined by the Board of Directors.

How many shares of common stock could be issued if the proposals are approved?

If the proposals are approved, FibroBiologics could issue up to 12,110,203 shares from the November 18 SPA, 4,477,614 shares from the November 24 SPA, 313,433 shares from the November 24 Engagement Letter, 5,227,275 shares from the December SPA, and 365,909 shares from the December Engagement Letter, totaling 22,184,434 shares.

Who controls the voting power at FibroBiologics' Special Meeting?

Pete O'Heeron, the Founder, CEO, and Chairperson, holds 2,500 shares of Series C Preferred Stock, each entitled to 13,000 votes. These shares are subject to an irrevocable proxy granted to the Board of Directors, which will cast 32,500,000 votes, representing 32.8% of the total votes eligible to be cast at the Special Meeting, FOR each of the proposals.

What is the record date for voting at the FibroBiologics Special Meeting?

The record date for the Special Meeting is December 26, 2025. Only stockholders of record at the close of business on this date are entitled to receive notice of and to vote at the Special Meeting or any postponement or adjournment thereof.

What are the potential risks for investors if these proposals are approved?

Investors face potential risks including significant dilution from the issuance of over 22 million new shares, which could depress the stock price. A reverse stock split, while aiming for Nasdaq compliance, does not guarantee long-term stock price appreciation and can sometimes be perceived negatively by the market, indicating underlying financial challenges.

What is Nasdaq Listing Rule 5635(d) and why is it relevant to FibroBiologics?

Nasdaq Listing Rule 5635(d) generally requires shareholder approval for the issuance of common stock, or securities convertible into common stock, in connection with a transaction other than a public offering, if the common stock to be issued is equal to 20% or more of the common stock or the voting power outstanding before the issuance. FibroBiologics needs approval for its recent warrant issuances to comply with this rule.

When and where will the FibroBiologics Special Meeting be held?

The Special Meeting of Stockholders for FibroBiologics, Inc. will be held on Friday, February 20, 2026, at 11:00 a.m. Central Time. It will be a virtual meeting accessible via the Internet at www.virtualshareholdermeeting.com/FBLG2026SM, originating from Houston, Texas.

What happens if a stockholder does not provide specific voting instructions to their broker?

If a beneficial owner of shares held in 'street name' does not provide specific voting instructions, their broker or bank may vote on 'routine' matters like the reverse stock split and adjournment proposal. However, they cannot vote on 'non-routine' matters, such as the stock issuance proposals, resulting in a 'broker non-vote' for those items.

What is the Board's recommendation for the proposals?

The Board of Directors of FibroBiologics urges stockholders to vote FOR each of the five proposals presented at the Special Meeting, including the reverse stock split, the three stock issuance proposals, and the adjournment proposal.

Risk Factors

Industry Context

FibroBiologics operates in the biotechnology sector, a highly competitive and capital-intensive industry. Companies in this space often rely on significant funding rounds and strategic corporate actions to advance research, development, and commercialization. The need for Nasdaq compliance highlights the pressure to maintain a certain market valuation and investor perception.

Regulatory Implications

The primary regulatory concern is maintaining compliance with Nasdaq listing rules, specifically Rule 5635(d), which necessitates shareholder approval for certain share issuances. Failure to obtain this approval could lead to delisting, posing a significant risk to the company's operations and market access.

What Investors Should Do

  1. Review the proposed reverse stock split ratio (1-for-5 to 1-for-30) and its potential impact on share price and liquidity.
  2. Understand the significant dilution resulting from the proposed issuance of up to 22,184,434 shares from recent financing activities.
  3. Evaluate the company's rationale for the Special Meeting and the necessity of these corporate actions for Nasdaq compliance.
  4. Consider the voting power of CEO Pete O'Heeron (32.8%) and the Board's stated intention to vote FOR all proposals when making your own voting decision.

Key Dates

Glossary

DEF 14A
A filing with the U.S. Securities and Exchange Commission (SEC) that provides detailed information about a company's annual meeting of shareholders, including executive compensation, board of directors, and voting matters. (This document contains the information being analyzed, outlining the proposals to be voted on at the Special Meeting.)
Reverse Stock Split
A corporate action where a company reduces the number of its outstanding shares by consolidating them into fewer, proportionally more valuable shares. (FibroBiologics is proposing a reverse stock split to increase its stock price and potentially meet Nasdaq listing requirements.)
Nasdaq Listing Rule 5635(d)
A rule requiring shareholder approval for the issuance of securities in connection with certain acquisitions or the sale of stock at a price below the lower of the book value or market value of the securities. (The company needs shareholder approval for recent share issuances to comply with this rule and avoid delisting.)
Securities Purchase Agreement (SPA)
A contract between a buyer and a seller that outlines the terms and conditions of a securities transaction. (FibroBiologics has entered into several SPAs, leading to the proposed issuance of new shares that require stockholder approval.)
Engagement Letter
A formal agreement outlining the terms of service between a client and a professional service provider, often related to financial transactions or advisory services. (Engagement letters related to recent financing activities are cited as a basis for additional share issuances requiring stockholder approval.)
Series C Preferred Stock
A class of preferred stock with specific rights and preferences, in this case, held by the CEO and carrying significant voting power. (The CEO's holdings of Series C Preferred Stock give him substantial voting control (32.8%) over the proposals.)

Year-Over-Year Comparison

This filing pertains to a Special Meeting called for February 20, 2026, focusing on immediate corporate actions like a reverse stock split and share issuances to maintain Nasdaq compliance. Information regarding year-over-year financial performance, revenue growth, margin changes, or the introduction of new risks compared to a previous filing is not directly available within this specific proxy statement, which is focused on upcoming shareholder votes rather than historical financial review.

Filing Stats: 4,776 words · 19 min read · ~16 pages · Grade level 11.8 · Accepted 2025-12-29 09:31:58

Key Financial Figures

Filing Documents

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 27 OTHER MATTERS 30 Stockholder Proposals for 2026 Annual Meeting 30 Householding of Proxy Materials 30 WHERE YOU CAN FIND MORE INFORMATION 31 Annex A – reverse stock split amendment 32 FIBROBIOLOGICS, INC. 455 E. Medical Center Blvd., Suite 300 Houston, Texas 77598 281-671-5150 PROXY STATEMENT FOR THE SPECIAL MEETING OF STOCKHOLDERS QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Why did I receive a notice regarding the availability of proxy materials on the Internet? Pursuant to rules adopted by the Securities and Exchange Commission, or the SEC, we have elected to provide access to our proxy materials over the Internet. Accordingly, we have sent you a Notice of Internet Availability of Proxy Materials, or the Notice, because the Board of Directors, or the Board, of FibroBiologics, Inc., or FibroBiologics, the Company, we, us or our, is soliciting your proxy to vote at the 2026 Special Meeting of Stockholders, or the Special Meeting, including at any adjournments or postponements of the meeting. All stockholders will have the ability to access the proxy materials on the website referred to in the Notice or request to receive a printed set of the proxy materials. Instructions on how to access the proxy materials over the Internet or to request a printed copy may be found in the Notice. We intend to mail the Notice on or about December 29, 2025 to all stockholders of record entitled to vote at the Special Meeting. Will I receive any other proxy materials by mail? We may send you a proxy card, along with a second Notice, on or after January 9, 2026. How do I attend the Special Meeting? Stockholders as of the record date and/or their authorized representatives are permitted to attend the Special Meeting. The Special Meeting will be held on Friday, February 20, 2026 at 11:00 a.m. Central Time virtually via the Internet at www.virtualshare

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing